Tuesday, April 9, 2013

Cleave Biosciences Adds $10M In Series A

Burlingame-based biopharmaceuticals developer Cleave Biosciences has raised another $10M in its Series A funding round, the firm announced today. According to Cleave, the new funding came from New Enterprise Associates. The funding brings its total raised in the Series A to $54M. Cleave's other investors include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners. The firm is focused on cancer treatments. More information »